AstraZeneca wins reprieve from Pulmicort generics; Merck's second Fosamax trial set to go;

@FiercePharma: Analysts expect nanotech drug delivery boom despite safety concerns. Article | Follow @FiercePharma

@EricPFierce: Pfizer recalls 52,000 bottles of its thyroid pill Levoxyl because of a bad odor. More | Follow @EricPFierce

> AstraZeneca ($AZN) has time to fight for its Pulmicort Respules patent, thanks to a court ruling that blocks generic copies till April 12. Report

> Merck's ($MRK) second Fosamax trial over claims involving femur fractures is set to begin next week after the first ended in a mistrial because the plaintiff developed a serious health complication. Report

> Navidea Biopharmaceuticals ($NAVB) said its diagnostic agent Lymphoseek effectively identified sentinel lymph nodes in patients with head and neck cancer, paving the way for expanded use of the drug. Report | More

> Mylan ($MYL) won the FDA's approval for its generic version of Valeant's herpes ointment Zovirax. Report

> Roche ($RHHBY) launched its new test for diagnosis and monitoring of thyroid cancer, Elacsys Calcitonin. Report | More

> Slovenia's Krka hiked its dividend by 7% to €1.61 ($2.07) per share. Report

> Australian officials said increasing the patent life on drugs has already cost the country $200 million a year in drug spending. Report

Medical Device News

@FierceMedDev: Dako gains FDA blessing for breast cancer antibody Dx agent. More | Follow @FierceMedDev

@MarkHFierce: Japan is dropping reimbursement rates for interventional cardiology devices. Not a good development for business. Story | Follow @MarkHFierce

 @DamianFierce: Bausch + Lomb has a date with the FDA for its intraocular lens implant. Article | Follow @DamianFierce

> New Dx chip allows for liquid diagnosis of prostate cancer advance. More

> Roche rolls out thyroid cancer Dx. Story

> Navidea touts PhIII data on Lymphoseek for head and neck cancer. Article

Biotech News

@FierceBiotech: #1 biotech billionaire on our list? @BillGates | Full report | Follow @FierceBiotech

@JohnCFierce: The biotech gods taketh away, and they giveth. Regeneron expanding, adding 400 jobs. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> Merrimack's lead lung cancer drug flunks first of three PhII tests. Article

> Can Merck use animal data to make its case against Lunesta, Ambien? More

> Bristol-Myers shuttering Amylin's San Diego HQ, laying off hundreds. Report

> Celgene-backed Agios and Foundation partner in breakthrough cancer strategy. News

Pharma Manufacturing News

> Industry ready to resurrect track and trace negotiations. Report

> Pfizer has another recall tied to smelly drugs. More

> Canada compounding pharmacy linked to weak chemo drugs. Story

> Frazier grabs AndersonBrecon as it bulks up in packaging. Article

Vaccines News

> JAMA paper delves into Merck staph vaccine flunk. Item

> Text message campaign fails to boost vaccination rate. Article

> U.S. keeping rubella at bay as virus takes toll globally. More

> Autism argument again undermined by vaccine data. Story

> Merck vax condemning pox to past. Report

And Finally... A monetary reason why Alzheimer's treatments are sorely needed: The cost of caring for dementia patients has risen to $109 billion annually, topping heart disease and cancer. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.